1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Carbonic Anhydrase

Carbonic Anhydrase

Carbonate dehydratase

Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct carbonic anhydrase enzyme families (α-, β-, γ- δ-, ζ-, η-, θ- and ι- CAs) were described to date. Carbonic anhydrases are involved in numerous physiological and pathological processes. Many of them are important therapeutic targets with the potential to be inhibited to treat a range of disorders including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.

The carbonic anhydrase reaction is involved in many physiological and pathological processes, including respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs; pH and CO2 homeostasis; electrolyte secretion in various tissues and organs; biosynthetic reactions (such as gluconeogenesis, lipogenesis, and ureagenesis); bone resorption; calcification; and tumorigenicity. α-CAs are Zn2+ metalloproteins expressed in animals, vertebrates, prokaryotes, fungi, algae, protozoa, and plants. Sixteen mammalian α-CA isoforms are known to be involved in many diseases such as glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-168767
    CA IX-IN-3
    Inhibitor
    CA IX-IN-3 (Compound 27) is a selective and potent carbonic anhydrase IX (CA IX) inhibitor with an IC50 of 0.48 nM.
    CA IX-IN-3
  • HY-13650R
    Indisulam (Standard)
    Inhibitor
    Indisulam (Standard) is the analytical standard of Indisulam. This product is intended for research and analytical applications. Indisulam (E 7070) is a carbonic anhydrase inhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15.
    Indisulam (Standard)
  • HY-159960
    Carbonic anhydrase inhibitor 28
    Inhibitor
    Carbonic anhydrase inhibitor 28 (Compound 11) is a Pseudomonas aeruginosa carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor 28 exhibits antimicrobial activity, with a MIC of 0.5 μg/mL and a MBC of 1 μg/mL against P. aeruginosa. Carbonic anhydrase inhibitor 28 can be used in anti-infection research.
    Carbonic anhydrase inhibitor 28
  • HY-B1480R
    Ethoxzolamide (Standard)
    Inhibitor
    Ethoxzolamide (Standard) is the analytical standard of Ethoxzolamide. This product is intended for research and analytical applications. Ethoxzolamide is a carbonic anhydrase inhibitor with Ki of 1 nM.
    Ethoxzolamide (Standard)
  • HY-163753
    Carbonic anhydrase inhibitor 25
    Inhibitor
    Carbonic anhydrase inhibitor 25 (compound 6a) is a potent carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor 25 shows inhibition for hCA I and hCA II receptor.
    Carbonic anhydrase inhibitor 25
  • HY-157321
    hCAI/II-IN-7
    Inhibitor
    hCAI/II-IN-7 (compound 1F) is a potent carbonic anhydrase (CA) inhibitor with Ki values of 23 nM, 44 nM and 20.57 µM for hCA-I, hCA-II and bovine CA, respectively.
    hCAI/II-IN-7
  • HY-172178
    hCAIX/XII-IN-14
    Inhibitor
    hCAIX/XII-IN-14 (Compound 1i) is an hCAIX/XII inhibitor, with Ki values of hCAII, hCAIX, and hCAXII for 9.4 nM, 5.6 nM, and 6.3 nM, respectively.
    hCAIX/XII-IN-14
  • HY-132155
    Indan-5-sulphonamide
    Inhibitor
    Indan-5-sulphonamide (Compd 1) is a carbonic anhydrase inhibitor and anticonvulsant agent, with Ki values of 0.039 nM (hCA XII), 6.5 nM (hCA XIV) and 5.1 nM (hCA XIV), respectively.
    Indan-5-sulphonamide
  • HY-B1056R
    Procodazole (Standard)
    Inhibitor
    DTA (Standard) is the analytical standard of DTA. This product is intended for research and analytical applications. DTA (2,4-Disulfamyl-5-trifluoromethylaniline) is a cyclic AMP phosphodiesterase inhibitor that binds to erythrocyte carbonic anhydrase.
    Procodazole (Standard)
  • HY-B0122S
    Topiramate-13C6
    Inhibitor
    Topiramate-13C6 (McN 4853-13C6) is the 13C labeled isotope of Topiramate (HY-B0122). Topiramate (McN 4853) is a broad-spectrum antiepileptic agent. Topiramate is a GluR5 receptor antagonist. Topiramate produces its antiepileptic effects through enhancement of GABAergic activity, inhibition of kainate/AMPA receptors, inhibition of voltage-sensitive sodium and calcium channels, increases in potassium conductance, and inhibition of carbonic anhydrase.
    Topiramate-<sup>13</sup>C<sub>6</sub>
  • HY-162226
    Carbonic anhydrase inhibitor 19
    Inhibitor
    Carbonic anhydrase inhibitor 19 (compound 26a) inhibits the Glaucoma related isoforms hCA II and hCA XII with Kis of 9.4 nM and 6.7 nM, respectively. Carbonic anhydrase inhibitor 19 reveals an intraocular pressure (IOP) lowering effect.
    Carbonic anhydrase inhibitor 19
  • HY-B1480S
    Ethoxzolamide-d5
    Inhibitor
    Ethoxzolamide-d5 (Redupresin-d5) is deuterium labeled Ethoxzolamide. Ethoxzolamide is a carbonic anhydrase inhibitor with Ki of 1 nM.
    Ethoxzolamide-d<sub>5</sub>
  • HY-B0109AS
    Dorzolamide-d3 hydrochloride
    Inhibitor
    Dorzolamide-d3 hydrochloride is deuterated labeled Dorzolamide hydrochloride (HY-B0109A). Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
    Dorzolamide-d<sub>3</sub> hydrochloride
  • HY-77036R
    Furagin (Standard)
    Inhibitor
    Furagin (Standard) is the analytical standard of Furagin. This product is intended for research and analytical applications. Furagin (Furazidine) is an analogue of Nitrofurantoin (HY-A0090) and has antibacterial activity. Furagin also inhibits human carbonic anhydrases (Kis: 260 and 57 nM for hCA IX and XII, respectively).
    Furagin (Standard)
  • HY-B0483R
    Tioxolone (Standard)
    Inhibitor
    Tioxolone (Standard) is the analytical standard of Tioxolone. This product is intended for research and analytical applications. Tioxolone is an inhibitor for the carbonic anhydrase. Tioxolone exhibits anti-leishmanial, antitumor, and anti-inflammatory activities. Tioxolone can be used in research of acne and psoriasis.
    Tioxolone (Standard)
  • HY-B0283R
    Acipimox (Standard)
    Inhibitor
    Acipimox (Standard) is the analytical standard of Acipimox. This product is intended for research and analytical applications. Acipimox (K-9321), a nicotinic acid analogue, is an antilipolytic compound. Acipimox stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.
    Acipimox (Standard)
  • HY-B0553R
    Methazolamide (Standard)
    Inhibitor
    Methazolamide (Standard) is the analytical standard of Methazolamide. This product is intended for research and analytical applications. Methazolamide (L584601) is a BBB-penetrable and orally active carbonic anhydrase inhibitor, with a Ki of 14 nM for human carbonic anhydrase II. Methazolamide can reduce intraocular pressure and has a neuroprotective effect, being able to inhibit neuronal apoptosis. Methazolamide can be used in the research of ophthalmic diseases such as glaucoma and cerebrovascular diseases such as subarachnoid hemorrhage.
    Methazolamide (Standard)
  • HY-B0124R
    Zonisamide (Standard)
    Inhibitor
    Zonisamide (Standard) is the analytical standard of Zonisamide. This product is intended for research and analytical applications. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
    Zonisamide (Standard)
  • HY-B0124S2
    Zonisamide-13C6
    Inhibitor
    Zonisamide-13C6 (AD 810-13C6) is 13C labeled Zonisamide. Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy.
    Zonisamide-<sup>13</sup>C<sub>6</sub>
Cat. No. Product Name / Synonyms Species Source

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.